The tweet was deleted by the author.
But we saved everything 🙂.
Candel Therapeutics, Inc. CEO Paul-Peter Tak joined a panel at BioEquityEurope focused on Patient Engagement Strategies.
During the discussion, Tak outlined how incorporating the patient perspective can shape the trajectory of innovation in drug discovery and development. The session emphasized the increasing importance of prioritizing patient needs to inform research directions and improve healthcare outcomes, especially for companies seeking to advance new therapies in the biotech sector.
View post on X Loading...
Candel Therapeutics is preparing to present new phase 3 trial follow-up data for its CAN-2409 immunotherapy in prostate cancer at AUA2026. The company has also advanced viral immunotherapies targeting prostate, lung, and brain cancers in its latest research drive, according to a recent update here. These initiatives highlight the firm's ongoing focus on clinical development in oncology.